Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

The ITC found that "multiple bad actors" have been importing or selling knockoff copies of Lilly's tirzepatide.

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

Tirzepatide treatment was associated with reduced body weight and diabetes risk across 3 years among individuals with obesity and prediabetes.

Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy ...

According to a recent release from GlobalData, Eli Lilly’s obesity offering could become a potential leader in the market.

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

A: an additional 90 days before any requirement on ICBs to fund tirzepatide, providing a 180‑day implementation ... dependent upon maturation of the obesity treatment pathway in primary care. NICE is ...